UK Halts Trial Of "Useless" Anti-Malaria Drug In COVID-19 Patients

Grant Boone
June 6, 2020

Controversy surrounding hydroxycholoquine and a related drug chloroquine has swirled for months, partly because Trump has urged people to try it and has taken it himself, even in the absence of a clear benefit.

"Hospitals contacted by The Guardian and other organisations have said that they didn't know anything about Surgisphere and hadn't handed over their data to them".

Bowser said whether or not there is a spike of cases as a result of protests, DC will still need to "accommodate anyone who gets sick".

Hydroxychloroquine has anti-inflammatory and antiviral properties and inhibited the virus in laboratory experiments.

Robert Califf, the former Food and Drug Administration commissioner and Alphabet employee, tweeted that the study "essentially rules out benefit of [hydroxychloroquine] in critically ill hospitalized patients".

The Oxford study is the largest so far to put hydroxychloroquine to a strict test.

Also, no evidence suggested that the anti-malarial drug would shorten the hospitalisation period.

At the time of publication the authors of the study published in The Lancet declared this large-scale study - in a long line of existing studies - as the most definite proof that the drug is ineffective against Covid-19.

More than 100 researchers have raised questions about the data behind the study and about Surgisphere, which had supplied it.

Mail-in primary enters last days
If people who've requested a mail-in ballot don't receive it before Election Day, they can cast a provisional one at the polls. Only four voters have registered and cast a ballot so far, while nine updated their registration and received a new ballot.

The participants were healthcare workers and people who had been exposed at home to ill spouses, partners or parents. While requesting to retract the studies from the journals, authors also apologised to the journals, the report said.

These were the details of the news "No benefit" from hydroxychloroquine for Covid-19 virus found in United Kingdom trial for this day. That difference was not statistically significant.

An influential article that found hydroxychloroquine increases the risk of death in coronavirus patients has been retracted over data concerns.

Boulware said his trial had fewer participants than initially planned because of difficulty enrolling new subjects after the FDA's warning.

A leading researcher in antibiotic resistance, Collignon regularly reviews academic papers before publication and said he always looks at the raw data. "We owe it to patients to have a definitive answer on whether or not a drug works", she said, adding that safety monitoring should also continue.

He called for doctors around the world to stop using the drug, which can cause a slew of nasty side effects including heart arrhythmias, headaches and vomiting. That publication led to the World Health Organization suspending its trials of the anti-malaria drug. That study is now being reexamined.

On Wednesday, WHO Director-General Dr. Tedros Adhanom Ghebreyesus announced that review was complete and that trial would be able to resume.

In addition, numerous doses reportedly given to patients in North America were higher than what's recommended by the U.S. Food and Drug Administration, Science reported.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER